Artificial intelligence can enhance virtual nursing, quality and outcomes, and healthcare transformation, says Dr. Stephanie Lahr, president of Artisight, a healthcare AI technology company. She shows how.
There are 13 startups from PharmaStars' cohort on digital innovation for women's health and health equity, and the accelerators' next cohort, Digital Innovations in Therapeutic Delivery. Naomi Fried, CEO and founder of PharmStars, offers a deep dive.
Edifecs is one company that's working to empower its female employees. The company's director of product marketing and senior director of corporate communications discuss some of those efforts.
Geisinger is using smart TVs to deliver to patients relevant, integrated clinical information, says Rebecca Stametz, VP of digital transformation at the company's Steele Institute for Health Innovation.
HIMSS23
Dr. Zenobia Brown, SVP of Population Health Care Management and associate CMO at Northwell Health, previews a HIMSS23 session on the use of technology to advance behavioral healthcare.
HIMSS23
Dr. Laura Jehi, the health system's chief research information officer, will speak with colleagues at HIMSS23 about how the Epic EHR and MyChart are helping to recruit participants for research initiatives such as the Cleveland Clinic BioRepository.
PharmStars' spring 2023 cohort will focus on women's health and health equity for underserved populations, says CEO Naomi Fried, who put forth a call for applications to digital health companies worldwide.
When is a virtual nurse needed? What are the skill sets required? What outcomes are hospitals seeing with virtual nursing? Lisbeth Votruba, RN, chief clinical officer at AvaSure, offers perspective.
The role of women in healthcare IT is evolving. Rebecca Woods, founder and virtual CIO of Bluebird Tech Solutions, explains how and describes how her nonprofit is working to inspire future female leaders.
HIMSS22 Europe
Well-informed and engaged patients are essential. Less red tape can help translate into better patient engagement, says Tarja Stenvall, SVP of key markets and general medicines at Sanofi.
